Tuberculosis Vaccine Trials

Trials Demonstrate Effective New Tuberculosis Vaccine

posted by Paul Fiddian | 07.09.2011

US research produces new vaccine with the potential to outperform current generation of treatments

A US-based research team has created a potential new human tuberculosis treatment drug that's already demonstrated its effectiveness and safety in trials involving mice.

Details of its performance appear in Nature Medicine, in a report that looks at the work carried out by a group at New York's Albert Einstein College of Medicine. This covers the TB vaccine's progression and trial phases and, while it establishes that it can work on mice, it warns that it might not yet be ready for human-based phased trials. That time, though, might not be too far away.

Data published by WHO (the World Health Organization) indicates that over 30 per cent of the global population can expect to contract TB and, each year, the disease claims approximately 1.7m lives. The situation's compounded by the rise of TB strains that drugs cannot destroy.

Effective New Tuberculosis Vaccine

The NY team decided that, in order to study how to produce an effective new tuberculosis vaccine, they'd look at how Mycobacterium tuberculosis - the bacteria responsible for TB - is able to suppress the immune system. They did this by examining another, closely-linked type of bacteria - Mycobacterium smegmatis.

While the smegmatis form is safe in human exposure terms, it kills mice at high concentrations.

Tuberculosis Vaccine Trials

Led by Professor William Jacobs, the team produced an artificial M. smegmatis variation which, when injected into the mice, produced a significantly higher survival rate, as he explained in a statement on the tuberculosis vaccine trials. "Most notably, those vaccinated animals that survived for more than 200 days had livers that were completely clear of TB bacteria, and nobody has ever seen that before", he said.

"We don't even know yet if it will work in humans, but it's certainly a significant step in efforts to create a better TB vaccine."

Pharma International previously looked at the work undertaken by scientists in the UK who, in March 2010, reported that they'd discovered a compound that could act as a platform on which to base future TB drug treatments.

Their announcement coincided with the annual World Tuberculosis Day.


Be the first one to add a comment

Add Comment

Fields marked with are required

Oops! Your comment was not submitted.

An internal error occurred during your comment submission. Please try again later or contact the system administrator.

The views and opinions expressed here are that of the individuals and are in no way related to Copybook Ltd.

Related Content

  • A person receiving an injection.

    New Discovery Could Help Toxoplasma Vaccine

    News pharmaceutical posted by Matthew Tranter | 02.11.2015

    Toxoplasma is a common parasitic infection that does not cause illness in the majority of people it infects. However, in some it can cause serious complications. Scientists have found a key pathway in the induc...

  • A chest x-ray

    Glaucoma Medication Could Treat TB

    News hospital posted by Matthew Tranter | 26.07.2015

    Tuberculosis is a global health concern with an estimated 2 billion infections worldwide. Drug resistance is a concern, so novel therapies are always being researched. An already-approved drug normally used to...

  • A person receiving a vaccine

    Vaccine Belief Waivers Voted Out by California Senate

    News pharmaceutical posted by Matthew Tranter | 15.05.2015

    California has voted to removed personal belief waivers for vaccines. This means children without a valid medical reason to not be vaccinated may be barred from public schools.

  • Cell Based Vaccine Production

    Cell Based Vaccine Production

    Video pharmaceutical posted by Sartorius | 17.04.2015

    Sartorius deliver a range of single use components for contaminant free pharmaceutical manufacturing. In this video, they discuss their cell-based vaccine production process in line with the single-use factory...

page up